These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
133 related items for PubMed ID: 7956716
1. Preliminary study of multiple increasing oral doses of dimethyl-APD on bone metabolism dynamics and safety profile. Vega E, Mautalen C, Roldán EJ, Pérez Lloret A. Drugs Exp Clin Res; 1994; 20(3):103-8. PubMed ID: 7956716 [Abstract] [Full Text] [Related]
2. Application of an in vitro model and a clinical protocol in the assessment of the potency of a new bisphosphonate. Papapoulos SE, Hoekman K, Löwik CW, Vermeij P, Bijvoet OL. J Bone Miner Res; 1989 Oct; 4(5):775-81. PubMed ID: 2816519 [Abstract] [Full Text] [Related]
3. Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. Schweitzer DH, Oostendorp-van de Ruit M, Van der Pluijm G, Löwik CW, Papapoulos SE. J Bone Miner Res; 1995 Jun; 10(6):956-62. PubMed ID: 7572320 [Abstract] [Full Text] [Related]
9. Treatment of Paget's bone disease with the bisphosphonate APD. Mautalen CA. Henry Ford Hosp Med J; 1983 Feb; 31(4):244-8. PubMed ID: 6425243 [No Abstract] [Full Text] [Related]
10. Intravenous aminopropylidene bisphosphonate (APD) in the treatment of Paget's bone disease. Vega E, Gonzalez D, Ghiringhelli G, Mautalen C. J Bone Miner Res; 1987 Aug; 2(4):267-71. PubMed ID: 3455613 [Abstract] [Full Text] [Related]
11. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone. Walsh JP, Ward LC, Stewart GO, Will RK, Criddle RA, Prince RL, Stuckey BG, Dhaliwal SS, Bhagat CI, Retallack RW, Kent GN, Drury PJ, Vasikaran S, Gutteridge DH. Bone; 2004 Apr; 34(4):747-54. PubMed ID: 15050907 [Abstract] [Full Text] [Related]
12. A single infusion of bisphosphonate AHPrBP in the treatment of Paget's disease of bone. Chakravarty K, Merry P, Scott DG. J Rheumatol; 1994 Nov; 21(11):2118-21. PubMed ID: 7869320 [Abstract] [Full Text] [Related]
13. Low dose intravenous 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD) for the treatment of Paget's disease of bone. Cantrill JA, Buckler HM, Anderson DC. Ann Rheum Dis; 1986 Dec; 45(12):1012-8. PubMed ID: 3813665 [Abstract] [Full Text] [Related]
15. Efficacy and tolerability of a new formulation of oral tiludronate (tablet) in the treatment of Paget's disease of bone. Reginster JY, Treves R, Renier JC, Amor B, Sany J, Ethgen D, Picot C, Franchimont P. J Bone Miner Res; 1994 May; 9(5):615-9. PubMed ID: 8053389 [Abstract] [Full Text] [Related]
16. Effective oral treatment of severe Paget's disease of bone with APD (3-amino-1-hydroxypropylidene-1,1-bisphosphonate); a comparison with combined calcitonin + EHDP (1-hydroxyethylidene-1,1-bisphosphonate). Fraser TR, Ibbertson HK, Holdaway IM, Rutland M, King A, Dodd G, Wattie DJ. Aust N Z J Med; 1984 Dec; 14(6):811-8. PubMed ID: 6442563 [Abstract] [Full Text] [Related]
19. [A single infusion of Pamidronate (APD) in Paget's disease of bone]. Thiébaud D, Jaeger P, Jacquet AF, Burckhardt P. Schweiz Med Wochenschr; 1989 Jan 21; 119(3):71-4. PubMed ID: 2711157 [Abstract] [Full Text] [Related]
20. A single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget's disease of bone. Thiébaud D, Jaeger P, Gobelet C, Jacquet AF, Burckhardt P. Am J Med; 1988 Aug 21; 85(2):207-12. PubMed ID: 3261129 [Abstract] [Full Text] [Related] Page: [Next] [New Search]